Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination (Q34997604)

5 August 2017

Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination (English)

1 reference

cost-effectiveness analysis

5 August 2017

1 reference

inferred from title

cervix uterine cancer

1 reference

Joshua A Salomon

3

0 references

Jeremy Goldhaber-Fiebert

series ordinal

1

object named as

Jeremy D Goldhaber-Fiebert

0 references

Sue Goldie

series ordinal

5

object named as

Sue J Goldie

1 reference

5 August 2017

4

Karen M Kuntz

1 reference

5 August 2017

Natasha K Stout

2

1 reference

PubMed ID

18314477

5 August 2017

language of work or name

English

0 references

publication date

26 February 2008

1 reference

Journal of the National Cancer Institute

5 August 2017

1 reference

5 August 2017

100

1 reference

5 August 2017

5

1 reference

5 August 2017

308-320

1 reference

Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination

5 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3099548

The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3099548

Cost-effectiveness of HPV 16, 18 vaccination in Brazil

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3099548

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3099548

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3099548

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3099548

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3099548

Model for assessing human papillomavirus vaccination strategies

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3099548

A public health approach to cervical cancer control: considerations of screening and vaccination strategies

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3099548

The natural history of cervical HPV infection: unresolved issues

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3099548

Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3099548

Chapter 10: New dimensions in cervical cancer screening

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3099548

Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3099548

Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3099548

Chapter 19: Cost-effectiveness of cervical cancer screening

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3099548

Chapter 18: Public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3099548

Collecting direct non-health care and time cost data: application to screening and diagnosis of cervical cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3099548

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3099548

Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3099548

Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS).

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3099548

Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3099548

An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3099548

An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3099548

The frequency of Pap smear screening in the United States

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3099548

Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3099548

ACOG Practice Bulletin: clinical management guidelines for obstetrician-gynecologists. Number 45, August 2003. Cervical cytology screening (replaces committee opinion 152, March 1995).

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3099548

Chapter 14: Role of triage testing in cervical cancer screening.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3099548

Chapter 13: Primary screening of cervical cancer with human papillomavirus tests

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3099548

Chapter 11: Future directions in cervical pathology

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3099548

Cost-effectiveness of a potential vaccine for human papillomavirus

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3099548

American Cancer Society guideline for the early detection of cervical neoplasia and cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3099548

2001 Consensus Guidelines for the management of women with cervical cytological abnormalities

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3099548

Race-specific results of Papanicolaou testing and the rate of cervical neoplasia in the National Breast and Cervical Cancer Early Detection Program, 1991-1998 (United States).

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3099548

Are pharmaceuticals cost-effective? A review of the evidence.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3099548

Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000.

8 July 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN019

Impact of the National Breast and Cervical Cancer Early Detection Program on mammography and Pap test utilization among white, Hispanic, and African American women: 1996-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN019

Cervical cancer screening among U.S. women: analyses of the 2000 National Health Interview Survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN019

Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN019

The health care costs of cervical human papillomavirus--related disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN019

Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN019

The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN019

Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN019

Benefits and costs of immunization of children with pneumococcal conjugate vaccine in Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN019

Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN019

Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN019

Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN019

Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN019

Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN019

Human papillomavirus and cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN019

Overview of the European and North American studies on HPV testing in primary cervical cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN019

Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN019

The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada

21 January 2018

1 reference

12 December 2020

Costs of running a universal adolescent hepatitis B vaccination programme

1 reference

12 December 2020

Cross-protection data for Gardasil submitted to FDA

1 reference

12 December 2020

Time costs associated with cervical cancer screening

1 reference

12 December 2020

Estimating CE ratios under second-order uncertainty: the mean ratio versus the ratio of means

1 reference

12 December 2020

Identifiers

DOI

10.1093/JNCI/DJN019

1 reference

5 August 2017

1 reference

5 August 2017

1 reference

PubMed ID

18314477